| Title |
Patient Preferences for the Treatment of Type 2 Diabetes: A Scoping Review
|
|---|---|
| Published in |
PharmacoEconomics, October 2013
|
| DOI | 10.1007/s40273-013-0089-7 |
| Pubmed ID | |
| Authors |
Susan M. Joy, Emily Little, Nisa M. Maruthur, Tanjala S. Purnell, John F. P. Bridges |
| Abstract |
As more studies report on patient preferences, techniques are needed to identify, assess and, eventually, synthesize results from a diverse set of methodologies. Data on patient preferences are valuable to decision makers in a variety of ways. Preferences for outcomes can be used to inform decision and cost-effectiveness models, while preferences for treatments can inform patient-centered outcomes research (PCOR) and patient-centered care. |
Mendeley readers
The data shown below were compiled from readership statistics for 151 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Indonesia | 1 | <1% |
| Canada | 1 | <1% |
| Switzerland | 1 | <1% |
| Unknown | 148 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 25 | 17% |
| Researcher | 21 | 14% |
| Student > Master | 19 | 13% |
| Student > Bachelor | 11 | 7% |
| Other | 10 | 7% |
| Other | 26 | 17% |
| Unknown | 39 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 40 | 26% |
| Nursing and Health Professions | 12 | 8% |
| Economics, Econometrics and Finance | 12 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 7% |
| Business, Management and Accounting | 7 | 5% |
| Other | 28 | 19% |
| Unknown | 41 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 March 2023.
All research outputs
#7,755,938
of 23,575,882 outputs
Outputs from PharmacoEconomics
#899
of 1,880 outputs
Outputs of similar age
#70,493
of 208,424 outputs
Outputs of similar age from PharmacoEconomics
#13
of 23 outputs
Altmetric has tracked 23,575,882 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,880 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 208,424 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.